ClinicalTrials.govpublic full text
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
carcinoma, renal cell, carcinoma colon, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 866150
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.